Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of long-term maraviroc use in a heterogeneous group of HIV-infected patients: A retrospective cohort study.

Author: HoepelmanA I M, MudrikovaT, WeehuizenJ M, WensingA M J, WitF W N M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Maraviroc is a well-tolerated and effective antiretroviral agent for HIV-1 infection. In a cohort study, long-term use was associated with good immunological and virological response.
Paper Details　
Original Abstract of the Article :
Since the registration of maraviroc (MVC) as an antiretroviral agent in 2008, only studies with a follow-up time of <5 years have been published. Therefore, little is known about its long-term safety and efficacy in clinical practice. In this cohort study, data on long-term follow-up of MVC treat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ijantimicag.2019.02.018

データ提供：米国国立医学図書館（NLM）

Long-Term Efficacy and Safety of Maraviroc in HIV-Infected Patients

This study explores the long-term efficacy and safety of maraviroc (MVC), an antiretroviral agent, in a diverse group of HIV-infected patients. It investigates the use of MVC in routine clinical practice, analyzing data from a retrospective cohort study spanning nearly 10 years. The study found that MVC-containing antiretroviral therapy (ART) was generally well-tolerated and resulted in significant improvements in immunological and virological responses, with a high proportion of patients achieving viral suppression. These findings provide valuable insights into the long-term effectiveness and safety of MVC in managing HIV infection.

Maraviroc: A Long-Term Ally in the Fight Against HIV

This study demonstrates the long-term efficacy and safety of maraviroc (MVC) in managing HIV infection. The study found that MVC-containing ART was generally well-tolerated and resulted in significant improvements in immunological and virological responses, with a high proportion of patients achieving viral suppression. These findings provide valuable reassurance regarding the long-term benefits of MVC in the management of HIV infection.

Navigating the Landscape of HIV Treatment

This research provides valuable information for patients navigating the complex landscape of HIV treatment. The study shows that maraviroc (MVC) can be a reliable and safe option for long-term management of HIV infection. It highlights the importance of personalized treatment strategies and close monitoring to ensure optimal outcomes for patients living with HIV.

Dr.Camel's Conclusion

This research offers a promising perspective on the long-term management of HIV infection. It highlights the efficacy and safety of maraviroc (MVC), providing valuable insights for patients and clinicians alike. This study underscores the importance of continuous research to develop effective and safe treatment strategies for HIV, enabling patients to live long and healthy lives.

Date :
  1. Date Completed 2019-12-03
  2. Date Revised 2019-12-03
Further Info :

Pubmed ID

30831236

DOI: Digital Object Identifier

10.1016/j.ijantimicag.2019.02.018

Related Literature

Article Analysis
・Side Effects of maraviroc
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.